Advertisement Pharmaceutical Business review - Page 5135 of 5291 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 21, 2026

Telix to acquire ITM in deal worth up to $2.35bn

Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.

Telix’s board has approved the transaction, and shareholders holding more than 90% of ITM shares had approved it at signing. Credit: Samuel Boivin / Shutterstock.com.